Experience

Davis Polk advised Signify Health on its acquisition of PatientBlox. The acquisition accelerates Signify’s prospective provider payment capabilities for episodes of care, supporting the…

Davis Polk is advising the special committee of the board of directors of China Biologic Products Holdings, Inc. (“China Biologic”) in connection with the going-private acquisition of China…

Davis Polk is advising Novo Nordisk A/S on its $1.8 billion acquisition of Emisphere Technologies Inc. and related Eligen SNAC royalty stream obligations owed to MHR Fund Management LLC,…

Davis Polk advised Coloplast on its acquisition of Nine Continents Medical, an early stage company pioneering an implantable tibial nerve stimulation treatment for over-active bladder. The…

Davis Polk advised Coloplast A/S in connection with its strategic equity investment in Francis Medical, Inc.Coloplast A/S is a Danish medical device company that develops products and…

Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion,…

Davis Polk is advising JP Morgan Securities LLC and Lazard as financial advisers to Aimmune Therapeutics in connection with its $2.6 billion sale to Sociétés des Produits Nestlé, S.A., a…

Davis Polk is advising Amwell on its agreement to form a multi-year, strategic partnership with Google Cloud to deliver transformative telehealth solutions across the global healthcare…

Davis Polk is advising JP Morgan Securities LLC as financial adviser to NN, Inc. in connection with the $825 million sale of its Life Sciences division to affiliates of American Securities…

Davis Polk is advising Bristol Myers Squibb on its acquisition of Forbius. The transaction includes an upfront payment and future success-based milestone payments. The transaction is…